COLL Stock Overview
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Collegium Pharmaceutical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.21 |
| 52 Week High | US$40.95 |
| 52 Week Low | US$20.95 |
| Beta | 0.93 |
| 11 Month Change | 11.90% |
| 3 Month Change | 5.94% |
| 1 Year Change | 49.14% |
| 33 Year Change | 76.29% |
| 5 Year Change | 225.34% |
| Change since IPO | 194.63% |
Recent News & Updates
Collegium Pharmaceutical: Diversifying And Growing
Aug 09Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking
Jul 24
Recent updates
Collegium Pharmaceutical: Diversifying And Growing
Aug 09Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking
Jul 24Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly
Jun 05Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'
May 13It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package
May 10Collegium Pharmaceutical Q4: The Beat Goes On
Feb 26These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues
Jan 05Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Oct 18Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jun 24Collegium Pharmaceutical: Oversold And Cheap
Jun 12Collegium Pharmaceutical: Thoughts After Another Strategic Move
Feb 20Shareholder Returns
| COLL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.4% | 2.3% | 3.1% |
| 1Y | 49.1% | 17.4% | 25.4% |
Return vs Industry: COLL exceeded the US Pharmaceuticals industry which returned 16% over the past year.
Return vs Market: COLL exceeded the US Market which returned 25.6% over the past year.
Price Volatility
| COLL volatility | |
|---|---|
| COLL Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: COLL has not had significant price volatility in the past 3 months.
Volatility Over Time: COLL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 197 | Mike Heffernan | www.collegiumpharma.com |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. Fundamentals Summary
| COLL fundamental statistics | |
|---|---|
| Market cap | US$1.16b |
| Earnings (TTM) | US$99.89m |
| Revenue (TTM) | US$576.65m |
11.7x
P/E Ratio2.0x
P/S RatioIs COLL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COLL income statement (TTM) | |
|---|---|
| Revenue | US$576.65m |
| Cost of Revenue | US$79.39m |
| Gross Profit | US$497.26m |
| Other Expenses | US$397.37m |
| Earnings | US$99.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.10 |
| Gross Margin | 86.23% |
| Net Profit Margin | 17.32% |
| Debt/Equity Ratio | 255.3% |
How did COLL perform over the long term?
See historical performance and comparison